TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting
(Thomson Reuters ONE) -
WALTHAM, Mass., Aug. 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an
oncology-focused biopharmaceutical company, today announced that data from nine
abstracts will be presented at the 2017 European Society for Medical Oncology
(ESMO) annual meeting, September 8 to September 12, 2017, in Madrid.
"We are excited that a wealth of data from the landmark ENGOT-OV16/NOVA trial
will be presented at this year's ESMO Annual Meeting," said Mary Lynne Hedley,
Ph.D., President and COO of TESARO. "Patient-reported quality of life data for
patients treated with niraparib versus placebo will be featured in an oral
presentation and the results of two post-hoc analyses, the observed exposure-
response relationship of niraparib in gBRCAmut and non-gBRCAmut patients, and
the safety and efficacy of niraparib in elderly patients, will be subjects for
poster discussions. In addition, data from the Phase 1/2 trial of niraparib plus
pembrolizumab in patients with triple-negative breast cancer or recurrent
platinum-resistant ovarian cancer (TOPACIO) will be highlighted in a poster
discussion. Finally, a poster will be presented detailing results from the Phase
1 study of TSR-042, our anti-PD-1 antibody."
Please plan to visit TESARO at Booth #53 for information about VARUBY(®) and our
pipeline.
Presentation Details (all times local):
ZEJULA(®) (niraparib)
Friday, September 8, 2017, 4:00 PM to 5:30 PM
Quality of life in recurrent ovarian cancer patients treated with niraparib:
Results from the ENGOT-OV16/NOVA TRIAL
Proffered Paper Session, Abstract: 930O, Location: Cordoba Auditorium
Saturday, September 9, 2017, 9:15 AM to 10:45 AM
Safety and efficacy of niraparib in elderly patients (Pts) with recurrent
ovarian cancer (OC)
Poster Discussion Session, Abstract: 934PD, Location: Cartagena Auditorium
Saturday, September 9, 2017, 9:15 AM to 10:45 AM
The exposure-response relationship of niraparib in patients (pts) with gBRCAmut
and non-gBRCAmut: results from the Phase 3 ENGOT-OV16/NOVA Trial
Poster Discussion Session, Abstract:933PD, Location: Cartagena Auditorium
Saturday, September 9, 2017, 1:15 PM to 2:15 PM
Modeling and impact of organ function on the population pharmacokinetics (PK) of
niraparib, a selective poly (ADP-ribose) polymerase (PARP)-1 and -2 inhibitor
Poster Display Session, Abstract: 964P, Location: Hall 8
Saturday, September 9, 2017, 1:15 PM to 2:15 PM
A randomized, double-blind, placebo-controlled multicenter phase 3 trial of
niraparib maintenance treatment in patients with advanced ovarian cancer
following frontline chemotherapy (PRIMA)
Poster Display Session, Abstract: 986TiP, Location: Hall 8
Saturday, September 9, 2017, 1:15 PM to 2:15 PM
A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib
combination therapy and determine the recommended phase 2 dose (RP2D) in women
with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)
Poster Display Session, Abstract: 953P, Location: Hall 8
Saturday, September 9, 2017, 1:15 PM to 2:15 PM
Disease burden during the "watchful waiting" period in patients with recurrent
ovarian cancer
Poster Display Session, Abstract: 962P, Location: Hall 8
Monday, September 11, 2017, 9:15 AM to 10:45 AM
Dose-finding combination study of niraparib and pembrolizumab in patients (pts)
with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-
resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
Poster Discussion Session, Abstract: 1143PD, Location: Bilbao Auditorium
Niraparib is marketed in the United States under trade name ZEJULA(®). Niraparib
has not been approved by any regulatory agencies outside of the United States.
The TOPACIO trial is being conducted in collaboration with Merck Sharp & Dohme
B.V., a subsidiary of Merck & Co., Inc., which is providing support for the
trial.
TSR-042 (anti-PD-1 antibody)
Sunday, September 10, 2017, 1:15 PM to 2:15 PM
Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti-PD-1
monoclonal antibody, in patients with advanced solid tumors
Poster Display Session, Abstract: 1185P, Location: Hall 8
About ZEJULA(®) (Niraparib)
Niraparib is marketed in the United States under trade name ZEJULA(®). ZEJULA
(niraparib) is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the
maintenance treatment of adult patients with recurrent epithelial ovarian,
fallopian tube, or primary peritoneal cancer who are in a complete or partial
response to platinum-based chemotherapy. In preclinical studies, ZEJULA
concentrates in the tumor relative to plasma, delivering greater than 90%
durable inhibition of PARP 1/2 and a persistent antitumor effect.
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including some fatal
cases, was reported in patients treated with ZEJULA. Discontinue ZEJULA if
MDS/AML is confirmed. Hematologic adverse reactions (thrombocytopenia, anemia
and neutropenia), as well as cardiovascular effects (hypertension and
hypertensive crisis) have been reported in patients treated with ZEJULA. Monitor
complete blood counts to detect hematologic adverse reactions, as well as to
detect cardiovascular disorders, during treatment. ZEJULA can cause fetal harm
and females of reproductive potential should use effective contraception. Please
see full prescribing information, including additional important safety
information, available at www.zejula.com.
About TSR-042
TSR-042 is a monoclonal antibody targeting PD-1 and was developed as part of the
collaboration between TESARO and AnaptysBio, Inc. This collaboration was
initiated in March of 2014, and is focused on the development of monospecific
antibody drugs targeting PD-1, TIM-3 (TSR-022), and LAG-3 (TSR-033), in addition
to a bi-specific antibody drug candidate targeting PD-1/LAG-3.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing
transformative therapies to people bravely facing cancer. For more information,
visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
Investor/Media Contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or jdavis(at)tesarobio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TESARO, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.08.2017 - 14:01 Uhr
Sprache: Deutsch
News-ID 557840
Anzahl Zeichen: 7494
contact information:
Town:
Massachusetts
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 356 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
TESARO, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
